Working… Menu

Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04091711
Recruitment Status : Not yet recruiting
First Posted : September 17, 2019
Last Update Posted : September 17, 2019
Information provided by (Responsible Party):
Dosentrx Ltd.

Brief Summary:

In recent decades, an increasing number of oral anticancer medications (oral oncolytics) have been approved. Oral oncolytics now make up to 30% of the oncology market, and their use is continually expanding.

Oral oncolytics can be a significant benefit for patients and providers. Patients who receive them often report a greater sense of control over their treatment, less interference with daily work and social activities, reduced travel time and costs, and the elimination of discomfort associated with an IV line. In rural areas, the oral route is crucial because the closest treatment center may be hours away and weather may complicate travel. Moreover, oral therapy is less invasive and reduces nursing time in infusion suites and risks to patients.

However, making cancer treatments available in oral form transfers most of the responsibility for correct administration of the drug to the patient. The more complex the oral treatment regimen, the higher the risk of errors and non-adherence. Oral Oncolytics are high-risk and high cost drugs. Hence, with this transfer of responsibility comes the need to support patients in their adherence to the directed regimen and to effectively monitor them at home.

Condition or disease Intervention/treatment Phase
Oncology Adherence, Medication Side Effect Device: ReX-C system Not Applicable

Detailed Description:
ReX is a hand-held, mobile device intended to provide solid oral medication on patient demand according to a pre-programmed treatment protocol. ReX addresses poor patient adherence, tracks patient's response to treatment and enhances patient engagement to therapy. The system comprises a reusable drug dispensing unit (Dispenser), a disposable Cassette containing the prescribed medication, a cellphone app, and the ReX cloud. The Dispenser manages pill administration. It includes a touch screen which guides the user and presents patient-specific clinical surveys and therapy information. The Dispenser contains a chargeable battery and indicators demonstrating device and battery status; a pill window enabling pills to be viewed; operational sensors; and communication to an app on cellphones. The patient receives the Cassette from the pharmacy, pre-filled with his/her specific medication. The Cassette is inserted into the Dispenser where it is locked in place. All therapy and patient survey data are transferred to a patient-specific domain on DosentRx' proprietary web-based cloud, named Dose-E®.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Open study for subjects receiving home-based oral oncolytic treatment. Subjects receive these medication by ReX-C device. Medication adherence, treatment instructions and side effects are recorded and monitored online in real time during the Study, by the ReX-C system.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate the Safety, Usability and Efficacy of the ReX-C® System in Measurement and Management of Medication Adherence and Clinical Self-reporting, in Oncology Patients Receiving Home-based Oral Oncolytic Therapy
Estimated Study Start Date : December 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : September 2020

Arm Intervention/treatment
Experimental: ReX-C intervention
Subjects use ReX-C to receive oral oncolytic medications. Adherence data, side effects and response to treatment are monitored online in real time via ReX-C cloud.
Device: ReX-C system
Oral oncolytic medications are dispensed to patients via ReX-C system

Primary Outcome Measures :
  1. Number of safety events during administration of oral oncolytic medications by ReX-C [ Time Frame: 8 weeks ]
    Safety events include: pill overdose, pill inhalation during pill ingestion, pill malformation upon dispensing and any severe adverse events related to pill intake by the ReX-C device.

  2. Rate of subjects feel comfortable to use ReX-C for pill intake and side effects report [ Time Frame: 8 weeks ]

    At least 70% of subjects: -

    • Complete the duration of the study with Rex-C.
    • Define the system as comfortable to use and are willing to continue using it for their oncolytic medication treatment.

  3. Rate of adherence (number of pill intakes) during treatment with ReX-C [ Time Frame: 8 weeks ]
    • Up to 90% of pills are taken as prescribed
    • At least 80% of subjects follow treatment instructions, and response to ReX-C reminders and alerts.

  4. Rate of monitoring subjects' home-based treatment by the clinical staff and satisfaction of the clinical team [ Time Frame: 8 weeks ]

    At least 80% of clinical team:

    • are satisfied with the use of the system and report that it is beneficial in monitoring patients' adherence and response to treatment.
    • report that the system facilitates better communication with the patient and provides more appropriate real-time response compared to routine care.
    • are interested in integrating the system into the oncology department for routine administration of home-based medication for oncology patients.

Secondary Outcome Measures :
  1. Number of actual pill intakes by ReX-C system, compared with the number of prescribed pills [ Time Frame: 8 weeks ]
    Test if the number of pills prescribed and given to the subjects is higher than that actually taken during the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or Female, at least 18 years of age
  2. Subject is able to swallow pills and during training successfully achieves 2 administrations of "demo" pills (Tic-Tac mints) by the ReX-C.
  3. Subject is able to read and understand the Informed Consent Form.
  4. Subject was diagnosed with cancer and receives oral oncology medication.
  5. Subject is intended to receive Afinitor OR Sutent OR Lenvima during the 2 months study period.
  6. Subject takes medication therapy at home.
  7. Subject is fluent in one of the following languages: Hebrew, English, Russian, Arabic.

Exclusion Criteria:

  1. Subject has physical or mental disabilities which prevents their enrolment in this study, such as poor fine motor skills, impaired visual or auditory faculties, mental disorders or other impairment affecting ability to provide Informed Consent or use the ReX-C dispensing unit effectively.
  2. Subject failed to extract 2 Tic-Tacs with the Rex-C device during training.
  3. Subject is participating in another clinical study that does not permit participation in two studies simultaneously.
  4. Subject is at end stage or terminal illness with anticipated life expectancy of less than 3 months.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04091711

Layout table for location contacts
Contact: Ronit Shtrichman, Ph.D +972526500938

Layout table for location information
Oncology Unit, Tel Aviv Sourasky Medical Center Not yet recruiting
Tel Aviv, Israel
Contact: Ravit Geva, MD    972-3-6973082   
Contact: Tali Schaffer, MPA    972-3-6972975   
Sponsors and Collaborators
Dosentrx Ltd.
Layout table for investigator information
Principal Investigator: Ravit Geva, MD Tel-Aviv Sourasky Medical Center

Layout table for additonal information
Responsible Party: Dosentrx Ltd. Identifier: NCT04091711     History of Changes
Other Study ID Numbers: RXC-034-2019-CLE
First Posted: September 17, 2019    Key Record Dates
Last Update Posted: September 17, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms